Shaanxi Key Laboratory of Degradable Biomedical Materials, School of Chemical Engineering, Northwest University, Taibai North Road 229, Xi'an, Shaanxi, 710069, China; Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Taibai North Road 229, Xi'an, Shaanxi, 710069, China; Biotech & Biomed Research Institute, Northwest University, Taibai North Road 229, Xi'an, Shaanxi, 710069, China.
Nutrition and Food Safety Engineering Research Center of Shaanxi Province, College of Public Health, School of Medicine, Xi'an Jiaotong University, Xi'an, 710061, China.
Food Chem Toxicol. 2019 Apr;126:277-284. doi: 10.1016/j.fct.2019.02.032. Epub 2019 Feb 28.
Alcoholic liver disease (ALD), as one of the most common diseases, has become a global threat to human health. The aim of this study was designed to investigate the hepatoprotective effects of ginsenoside Rk3 against ALD and to discover the potential mechanisms of these protective effects. Mice were intragastrically administered 50% alcohol and treated with ginsenoside Rk3 (25 and 50 mg/kg) once per day for 6 weeks. The results indicated that ginsenoside Rk3 promoted hepatic function through significant downgrading AST and ALT levels in the serum, attenuating oxidative stress, and restoring antioxidant balance in hepatic tissue. Additionally, ginsenoside Rk3 significantly reduced the expression of inflammatory cytokines, such as NF-κB, TNF-α, IL-6, and IL-1β in the mice. Furthermore, ginsenoside Rk3 supplementation significantly inhibited apoptotic protein expression in the liver. The present study clearly demonstrates that ginsenoside Rk3 exerts a protective effect against ALD-induced liver injury because of its antioxidant, anti-apoptotic, and anti-inflammatory activities. The findings from the present investigation show that ginsenoside Rk3 might be a promising candidate treatment agent against ALD.
酒精性肝病 (ALD) 作为最常见的疾病之一,已成为全球人类健康的威胁。本研究旨在探讨人参皂苷 Rk3 对 ALD 的保护作用,并发现这些保护作用的潜在机制。小鼠经灌胃给予 50%酒精,并每天给予人参皂苷 Rk3(25 和 50mg/kg)一次,持续 6 周。结果表明,人参皂苷 Rk3 通过显著降低血清中天冬氨酸转氨酶和丙氨酸转氨酶水平、减轻氧化应激以及恢复肝组织抗氧化平衡,促进肝功能。此外,人参皂苷 Rk3 还显著降低了小鼠肝脏中 NF-κB、TNF-α、IL-6 和 IL-1β 等炎症细胞因子的表达。此外,人参皂苷 Rk3 补充剂显著抑制了肝脏中凋亡蛋白的表达。本研究清楚地表明,人参皂苷 Rk3 通过抗氧化、抗凋亡和抗炎活性对酒精性肝损伤发挥保护作用。本研究的结果表明,人参皂苷 Rk3 可能是治疗酒精性肝病的有前途的候选药物。